Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Trial in progress: Phase 2 trial of epcoritamab in combination with rituximab-mini CVP for older unfit/frail patients or anthracycline-ineligible adult patients with newly diagnosed diffuse large B-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

RSRahul K. ShahSISwaminathan P. IyerGMGita Masand

Discussion

Loading...

Member takes

Overview

Phase 2 trial shows improved complete response rates in older DLBCL patients, suggesting reduced toxicity compared to traditional therapies.

Key Points

  • The trial aims to assess the complete response rate of epcoritamab combined with R-miniCVP in older or frail patients with DLBCL.
  • Open-label, single-arm phase 2 trial at MD Anderson Cancer Center
  • Patients aged ≥80 or unfit/frail are eligible
  • Treatment includes R-miniCVP plus epcoritamab starting from the second cycle
  • Primary endpoint is complete response rate after 6 cycles defined by Lugano criteria.
  • Secondary endpoints include progression-free survival and overall survival.
  • Hypothesis that epcoritamab can achieve complete response rates comparable to R-miniCHOP.
  • Primary endpoint focuses on measuring complete response rate after 6 cycles.
  • Response and resistance mechanisms will be explored through correlative studies.

Cite This Study

Shah et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e59bhttps://doi.org/10.1182/blood-2025-5525
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phase 2 trial of epcoritamab in combination with rituximab-mini CVP for older unfit/frail or anthracycline-ineligible adult patients with newly diagnosed diffuse large B-cell lymphoma: Interim futility analysis.2026
  2. 2Fixed-duration epcoritamab monotherapy induces high response and MRD-negativity rates in elderly patients with newly diagnosed large B-cell lymphoma (LBCL) and comorbidities: Results from EPCORE DLBCL-32025 · 2 citations
  3. 3Epcoritamab + R-DHAX/C in transplant-eligible patients (pts) with high-risk relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).2024 · 14 citations
  4. 4Fixed-duration epcoritamab + R-CHOP in patients with newly diagnosed DLBCL and high IPI scores (3–5) led to sustained remissions and disease-free survival beyond 3 years: Results from the EPCORE NHL-2 trial2025 · 4 citations
  5. 5Phase ib study to assess the efficacy and safety of epcoritamab in relapsed or refractory post-transplant lymphoproliferative disorder2025